TBPH - Theravance Biopharma Inc
Theravance Biopharma Inc Logo

TBPH - Theravance Biopharma Inc

https://www.theravance.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Protagonist Therapeutics ( NASDAQ:PTGX ) , StandardAero ( NYSE:SARO )
Benzinga • 3 days, 3 hours ago • score: 0.36
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B. Riley Securities analyst Mayank Mamtani initiated coverage on Theravance Biopharma, Inc.
Bullish
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Artivion ( NYSE:AORT ) , Coinbase Global ( NASDAQ:COIN )
Benzinga • 2 months, 4 weeks ago • score: 0.15
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Canaccord Genuity analyst William Plovanic initiated coverage on Artivion, Inc.
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.

52W High
$14.55
52W Low
$7.88
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
0.05
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
58.12
Forward P/E (<15 better)
9.43
EV/EBITDA (<8 favorable)
8.90
EV/Revenue (<3 favorable)
5.31
P/S (TTM) (<3 favorable)
9.10
P/B (<3 favorable)
3.12
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
4.37%
Institutions (25–75% balanced)
92.05%
Shares Outstanding
50,361,000
Float
21,894,600
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
77,205,000
Gross Profit (TTM)
36,542,000
EPS (TTM)
0.24
Profit Margin (>10% good)
0.17%
Operating Margin (TTM) (higher better)
-0.10%
ROE (TTM) (>15% strong)
0.06%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.84
Momentum
Bearish momentum
Value
0.5365
Previous
0.5149
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025